RASP (Actavia Life Sciences) EBITDA Margin %: 0.00% (As of Mar. 2024)


What is Actavia Life Sciences EBITDA Margin %?

Actavia Life Sciences RASP -87.50% EBITDA Margin % is 0.00% as of Mar. 2024.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Actavia Life Sciences's EBITDA for the three months ended in Mar. 2024 was $-0.07 Mil. Actavia Life Sciences's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Actavia Life Sciences's EBITDA margin for the quarter that ended in Mar. 2024 was 0.00%.

Actavia Life Sciences  (OTCPK:RASP) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Actavia Life Sciences EBITDA Margin % Related Terms

Actavia Life Sciences EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Actavia Life Sciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actavia Life Sciences EBITDA Margin % Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Actavia Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RASP vs BWV, FNCH, CWBR: EBITDA Margin % Comparison

For the Biotechnology subindustry, Actavia Life Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actavia Life Sciences EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actavia Life Sciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Actavia Life Sciences's EBITDA Margin % falls into.


Actavia Life Sciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Actavia Life Sciences's EBITDA Margin % for the fiscal year that ended in Sep. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Sep. 2023 )/Revenue (A: Sep. 2023 )
=-4.23/0
= %

Actavia Life Sciences's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-0.071/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Actavia Life Sciences (RASP) has a EBITDA Margin % of 0.00% as of Mar. 2024. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Actavia Life Sciences and its competitors.
Is Actavia Life Sciences' EBITDA Margin % too high?
Actavia Life Sciences' current EBITDA Margin % is 0.00%.
How does Actavia Life Sciences' EBITDA Margin % compare to BWV and FNCH?
Actavia Life Sciences' EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Actavia Life Sciences and its competitors. Actavia Life Sciences's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actavia Life Sciences stock overvalued right now?
Actavia Life Sciences (RASP) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Actavia Life Sciences (RASP), the current EBITDA Margin % is 0.00% as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actavia Life Sciences Business Description

Address 5 Penn Plaza, No.1954, 19th Floor, New York, NY, USA, 10001
Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.